Treatment with an AMPA Antagonist 12 Hours following Severe Normothermic Forebrain Ischemia Prevents CA1 Neuronal Injury
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The neuroprotective effects of 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo( f)quinoxaline (NBQX), GYKI 52466, and MK-801 were tested following severe forebrain ischemia. Wistar rats were subjected to 10 min of normothermic ischemia and reperfused for 7 days. Necrotic hippocampal CA 1 neurons were counted and expressed as a percentage (mean ± SD). In Experiment 1, saline-treated rats sustained 81 ± 20% damage to dorsal CA 1. Rats given NBQX 30 mg/kg i.p. x 3 lost 21 ± 27% (p < 0.01). Neither MK-801 1 mg i.p. x 3 alone, nor in combination with the cytoprotective dose of NBQX protected CA 1, with 83 ± 18 and 54 ± 34% damage, respectively (NS). Giving NBQX 90 mg/kg i.v. did not protect cells (94 ± 5%) and resulted in nephrotoxicity. In Experiment 2, rats were given saline or three doses of NBQX 30 mg/kg i.p. immediately at reperfusion (RP) or after a 6-, 12-, or 24-h delay. Saline-treated rats suffered 79 ± 16% injury. NBQX given immediately resulted in 17 ± 17% injury, and even if treatment was delayed by either 6 or 12 h, there was marked protection with only 27 ± 32 and 25 ± 17% injury, respectively (all p < 0.01). Delaying the initiation of treatment to 24 h was not successful, resulting in 50 ± 28% injury (NS). In Experiment 3, saline-treated rats lost 81 ± 19% of CA 1 cells, while those given GYKI 52466 10 mg/kg i.p. x 5 starting immediately following RP lost 80 ± 14%. Blocking α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors with NBQX postischemia is highly efficacious, indicating that delayed degeneration of CA 1 cells is AMPA rather than N-methyl-d-aspartate (NMDA) receptor-linked and is reversible for CA 1 cells for at least 12 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia
Sheardown, M. J., Nielsen, E. Ø., Hansen, A. J., Jacobsen, P., & Honoré, T. (1990) · Science · doi:10.1126/science.2154034 · Cited by 1,138
Iino, M., Ozawa, S., & Tsuzuki, K. (1990) · The Journal of Physiology · doi:10.1113/jphysiol.1990.sp018060 · Cited by 497
Buchan, A. M., Li, H., Cho, S., & Pulsinelli, W. A. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90314-j · Cited by 255 · cited 1×
“Data are also now emerging that indicate that both NBQX and GYKI 52466 can also protect the cortex in the wake of focal ischemia (Buchan et al., 1991c; Gill et al., 1992; Smith and Meldrum, 1992; D. Xue et al., unpublished data).”
BackgroundSelf-citationProtection against ischemic hippocampal CAI damage in the rat with a new non-NMDA antagonist, NBQX
Diemer, N. H., Jørgensen, M. B., Johansen, F. F., Sheardown, M., & Honoré, T. (1992) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1992.tb08052.x · Cited by 106
Cited by
Ischemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Neuropharmacology of AMPA and kainate receptors
Bleakman, D., & Lodge, D. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00139-7 · Cited by 363
Obrenovitch, T. P., & Urenjak, J. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00049-4 · Cited by 307
Metadata
- Authors
- Li, H., & Buchan, A. M.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 1993-11
- Volume
- 13
- Issue
- 6
- Pages
- 933-939
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W1979129896
- Cited by
- 150
- References
- 4
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.